By using this website, you agree to the storing of cookies on your device. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookie Policy.

June 14, 2022

Slingshot Biosciences, Inc. Partners With Almog Diagnostic To Distribute Synthetilc Cells Throughout Israel

Selina Yee

Emeryville, CA (June 14, 2022) – SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that
bring consistent precision and accurate control to replace inconsistent blood and tissue controls for
use in flow cytometry and other biotech markets, today announced they have extended their
distribution channel through a new agreement with Almog Diagnostic, a private company established
in 1987 and is active ever since in the Israeli biotech market. Almog offers innovative products and
services in the fields of immunology/hematology, immunotherapy (CGT), stem cell biology, cell
separation, flow cytometry, bioprinting, gene expression, molecular and cell biology, and microbiology.
Almog is a major player in the Israeli flow cytometry field for over 13 years, with the automated
MACSQuant (Miltenyi Biotec) and the innovative Aurora Spectral Flow Cytometer (Cytek
Biosciences), in addition to providing advanced CRO flow cytometry services.

The agreement entitles Almog Diagnostic to the right to distribute and resell Slingshot Bio’s products
in Israel. Through Almog Diagnostic’s network of customers, Slingshot Bio will be able to establish its
presence in the Israel market with the well-established presence and expertise of Almog Diagnostic
which has been selling into flow cytometry for many years.

“Almog Diagnostic’s network will provide us with the market penetration needed to reach our full sales
potential. Slingshot Biosciences has considered many distribution partners and we are confident that
Almog Diagnostic’s extensive knowledge in the field, prominent presence, and large customer base
will help us leverage our position in the flow cytometry market”, said Jeffrey Kim, CEO & Founder.

Slingshot Bio’s synthetic cellular controls provide consistent, precise, and accurate control for
research users in the flow cytometry space by mimicking blood properties as detected by flow
cytometry. The ability to manufacture consistent controls for flow cytometry has been missing for
decades and is now accurately reproducible with Slingshot Bio’s unique manufacturing platform. “As
the distributor of the spectral flow cytometer from Cytek in Israel, we are really excited to collaborate
with Slingshot and provide our customers the best solution for assay and instrument control” said,
Nitsan Levi, VP New Technologies and Implementation at Almog.

About Slingshot Biosciences, Inc.
Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform
technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based
applications—including diagnostics, and adoptive cell therapy development and instrument calibration.

Learn more at www.slingshotbio.com